“Scientists and clinicians in the early phases of their career are crucial to our mission to end cancer and play a central role in driving innovation in all areas of cancer research, prevention, diagnosis and treatment,” said Giulio Draetta, M.D., Ph.D., chief scientific officer at MD Anderson. “We congratulate these junior investigators on receiving such notable recognition from AACR for their high-impact work.”
Navin: Outstanding Achievement in Basic Cancer Research
This prestigious AACR scientific achievement award was established to recognize an early career investigator for achievements in basic cancer research. Navin was selected for his seminal contributions to the understanding of genome evolution and intratumor heterogeneity in breast cancer and for his invention of single-cell DNA sequencing, which has impacted many diverse fields of biology and biomedicine and has directly contributed to the establishment of the single cell genomics field.
E-Mail
IMAGE: (left to right) Kimryn Rathmell, Bradley Reinfeld, Matthew Madden and Jeffrey Rathmell have discovered that immune cells not cancer cells are the major glucose consumers in the tumor. view more
Credit: Susan Urmy/VUMC
Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.
Instead, non-cancer cells in a tumor primarily immune cells called macrophages have the highest glucose uptake, the group reported April 7 in the journal
Projects & Studies
Description
The Acute Effects of Exercise on Breast Cancer Biomarkers (ACE Study) is enrolling women to test the effect of moderate intensity exercise on cancer risk factors such as biomarkers in healthy women. Knowing if exercise significantly alters these biomarkers, could help support guidelines for daily exercise for breast cancer prevention and could indicate that exercise even without weight loss is beneficial.
Advanced Colorectal Cancer of Serrated Subtype (ACCESS) Study
Description
Funding Agency: National Institutes of Health
Advancing our Understanding of the Etiologies and Mutational Landscapes of Basal-like, Luminal A, and Luminal B Breast Cancer
Description
Addressing research gaps in the molecular subtypes of breast cancer, we are taking a multidisciplinary approach to study the epidemiology and mutational landscapes of basal-like, luminal A, and luminal B tumors.
Rain Therapeutics Appoints Richard Bryce, MBChB, as Executive Vice President and Chief Medical Officer globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Session Category: Molecular and Cellular Biology/Genetics
Session Title: Genomic Profiling of Tumors
Permanent Abstract Number: 2234
Authors: Xiaobo Chen, Huan Tian, Wubin Qian, Henry Q. Li, Sheng Guo. Crown Bioscience Inc, Suzhou, China, Crown Bioscience Inc, San Diego, CA
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument,